GDP-D-glucose Phosphorylase 1: A Potential Drug Target (G390637)

Target Name: GDPGP1

NCBI ID: G390637

GDPGP1

GDP-D-glucose Phosphorylase 1: A Potential Drug Target

GDP-D-glucose phosphorylase 1 (GDP1) is a protein that is expressed in various tissues and cells in the body. It is a key enzyme in the glucose metabolism pathway, which is responsible for the breakdown of glucose to produce energy. GDP1 is a critical enzyme in the pathway, as it helps to regulate the rate at which glucose is phosphorylated and converted to use as energy by the cell.

GDP1 is a 26kDa protein that is expressed in the liver, muscle, and heart. It is highly expressed in the liver, with lower levels found in muscle and heart. GDP1 is also expressed in various other tissues, including the kidneys, pancreas, and red blood cells. It is a type of glycogen phosphorylase, which means that it adds a phosphate group to the amino acid glycine.

GDP1 is involved in the glucose metabolism pathway at multiple levels. It is the first enzyme in the pathway that adds a phosphate group to the amino acid glycine. This event is critical, as the addition of a phosphate group allows the glucose to be converted to glucose-6-phosphate, which is the first step in the pathway for producing energy. GDP1 is also involved in the regulation of the rate at which glucose is phosphorylated and converted to use as energy by the cell.

In addition to its role in the glucose metabolism pathway, GDP1 is also a potential drug target. Several studies have suggested that GDP1 may be a potential target for drug development due to its unique mechanism of action and its involvement in the glucose metabolism pathway.

One potential mechanism by which GDP1 may be targeted by drugs is its role in the regulation of the rate at which glucose is phosphorylated and converted to use as energy by the cell. Drugs that inhibit the activity of GDP1 have been shown to increase the rate at which glucose is phosphorylated and converted to use as energy by the cell. This increase in glucose availability can lead to an increase in the body's energy needs, which can lead to various health benefits.

Another potential mechanism by which GDP1 may be targeted by drugs is its role in the regulation of inflammation. GDP1 has been shown to be involved in the regulation of inflammation in various tissues. It has been shown to play a key role in the regulation of the immune response and has been shown to contribute to the regulation of inflammation in the liver.

In conclusion, GDP-D-glucose phosphorylase 1 is a protein that is involved in the glucose metabolism pathway and has been shown to play a key role in the regulation of the rate at which glucose is phosphorylated and converted to use as energy by the cell. As a result, GDP1 is a potential drug target and may be a useful target for the development of new treatments for a variety of diseases.

Protein Name: GDP-D-glucose Phosphorylase 1

Functions: Specific and highly efficient GDP-D-glucose phosphorylase regulating the levels of GDP-D-glucose in cells

The "GDPGP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDPGP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets